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Background: Progress in recent years strengthened the concept of cellular tumor vaccinations. However, a crucial
barrier to successful cancer immunotherapy is tumor-mediated immunosuppression. Tumor-derived soluble factors
such as IL-10, TGF-β, and VEGF suppress effector cells either directly or indirectly by disruption of dendritic cell (DC)
differentiation, migration and antigen presentation. Human B cells acquire potent immunostimulatory properties
when activated via CD40 and have been shown to be an alternative source of antigen-presenting cells (APCs) for
cellular cancer vaccines. Nevertheless, in contrast to DCs little knowledge exists about their susceptibility to tumor
derived immunosuppressive factors. Thus, we assessed whether IL-10, TGF-β, or VEGF do affect key aspects of the
immunostimulatory function of human CD40-activated B cells.
Methods: Cell surface expression of adhesion and costimulatory molecules and the proliferation capacity of CD40-
activated B cells were compared to untreated controls by flow cytometry. Migration towards important chemokines
of secondary lymph organs was measured with or without exposure to the immunosuppressive cytokines. Finally,
an influence on T cell stimulation was investigated by allogeneic mixed lymphocyte reactions. For statistical analysis
Student’s t test or two-way analysis of variance followed by Bonferroni's post-hoc test was used to compare groups.
P values of <0.05 were considered statistically significant.
Results: Neither cell adhesion nor the expression of MHC class II and costimulatory molecules CD80 and CD86 was
inhibited by addition of IL-10, TGF-β, or VEGF. Likewise, the proliferation of CD40-activated B cells was not impaired.
Despite being exposed to IL-10, TGF-β, or VEGF the B cells migrated equally well as untreated controls to the
chemokines SLC and SDF-1α. Most importantly, the capacity of CD40-activated B cells to stimulate CD4+ and CD8+
T cells remained unaffected.
Conclusion: Our findings suggest that key immunostimulatory functions of CD40-activated B cells are resistant to
inhibition by the immunosuppressive factors IL-10, TGF-β, and VEGF. This supports considerations to use ex vivo
generated CD40-activated B cells as a promising alternative or additional APC for cellular immunotherapy, especially
in settings where these immunosuppressive cytokines are present in tumor environment.
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The immune system plays an important role in the con-
trol of tumor development and progression. Thus, since
decades immunotherapeutic strategies aim to exploit the
ability of the immune system to detect and destroy
tumor cells. One of the most promising concepts is the
use of antigen-presenting cells (APCs) as cellular adju-
vants for tumor vaccination. Especially, dendritic cells
(DCs) have been identified as the ideal APC source due
to their natural antigen-processing and presenting
functions, their migratority capacities and the ability to
activate naïve T cells [1]. However, a general barrier to
successful cancer immunotherapy is the tumor-induced
immunosuppression which is mainly mediated by tumor-
derived soluble factors in the tumor microenvironment
[2,3]. This is also true for APC-based tumor vaccinations
strategies [4].
Among the most well-known and best characterized
tumor-derived immunosuppressive molecules are inter-
leukin-10 (IL-10) [5,6], transforming growth factor-beta
(TGF-β) [7,8], and vascular endothelial growth factor
(VEGF) [9,10]. An important mechanism by which IL-
10, TGF-β, and VEGF counteract the development of an
anti-tumor immune response is through inhibition of
DC differentiation, maturation, trafficking, and antigen
presentation [6,11].
In recent years the antigen-presenting function of B
lymphocytes has gained increasing attention. Accumulat-
ing evidence demonstrates that B cells serve many func-
tions in the immune response beside antibody mediated
mechanisms [12]. Cytokine production and antigen-pres-
entation are important mechanisms by which B lympho-
cytes contribute to both to immunity and immune
pathology [13–16]. Activated antigen-presenting B cells
have been shown to efficiently induce both CD4+ and
CD8+ T cells responses in vitro and in vivo [17–20].
Therefore, many research groups are currently evaluating
B cell-based vaccines as an alternative to DC-based vac-
cines for cancer immunotherapy [18,19,21–27].
CD40-activated B cells can be prepared at relatively
low costs as a highly pure homogenous population that
can be expanded from small amount of peripheral blood
even from cancer patients [28]. However, it is not known
whether tumor-derived immunosuppressive factors affect
the antigen-presenting capacity of CD40-activated B cells
in a similar fashion as in DC. We therefore studied the
effect of IL-10, TGF-β, and VEGF on the phenotype, mi-
gratory ability, and T cell stimulatory capacity of CD40-
activated B cells in vitro.
Methods
Flow cytometry
Immunophenotypic analysis was performed using fluor-
escence-activated cell sorting (FACS) according tostandard protocols. The cells were analyzed on a FACS-
Canto flow cytometer (BD Biosciences, Heidelberg, Ger-
many). Antibodies against CD19, CD80, CD86, HLA-DR,
CD3, and CD25 were purchased from BD Pharmingen
(Heidelberg, Germany).Generation of CD40-activated B cells and cell culture
CD40-B cells were generated as described previously
[29]. In brief, whole PBMC were cultured on irradiated
NIH3T3 fibroblasts transfected with human CD40 ligand
(tCD40L) in the presence of recombinant human
interleukin-4 (2 ng/ml; R&D Systems, Minneapolis, MN,
USA) and clinical-grade cyclosporin A (CsA, 55×10−7 M;
Novartis, Basel, Switzerland) in Iscove's modified Dulbecco's
medium (IMEM; Invitrogen, Karlsruhe, Germany) sup-
plemented with 10% pooled human serum. The expand-
ing cells were transferred onto freshly prepared tCD40L
cells and fed with cytokine-replenished medium with-
out CsA every 3–4 days. After 2–3 weeks in culture the
CD40-activated B cells had a purity of >95 % and were
used for the experiments. Therefore they were cultured
for 4 days in the presence of 40 ng/ml IL-10, 10 ng/ml
TGF-β, 20 ng/ml VEGF or vehicle as a control. For
these concentrations the inhibitory effects on APC
functions of DCs have been demonstrated previously
[11]. Prior to use the activity of IL-10, TGF-β, and
VEGF at the given concentrations was tested by asses-
sing their inhibitory effect on DC maturation and for
IL-10 and TGF-β additionally on T cell proliferation.In vitro migration assay
To assess B cell migration, 5 × 105 CD40-B cells were
transferred into the upper chamber of 5-μm pore size
transwell plates (Costar, Cambridge, MA, USA). Varying
amounts of the chemokines SDF-1α and SLC (R&D Sys-
tems) were added to the lower chamber. After 2 hours at
37°C, the number of cells that had migrated into the
lower chamber was determined using a hemacytometer.T cell proliferation assay
Untouched CD4+ T cells and CD8+ T cells were obtained
from buffy coats by negative selection using Rosette SepW
(StemCell Technologies) human CD4+ and CD8+ T cell
enrichment cocktails according manufacturers’ instructions.
Prior to allogeneic mixed lymphocyte reactions (MLR) the
CD4+ and CD8+ T cells were labeled with carboxyfluores-
cein diacetate succinimidyl ester (CFSE, Molecular Probes)
according to standard protocols. A total of 1 x105
CFSE-labeled CD4+ or CD8+ T cells were co-incubated
with allogeneic CD40-B cells as stimulators at different B to
T cell ratios ranging from 1:1 to 1:20. After 5–7 days prolif-
eration was assessed by flow cytometry.
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Data are reported as means ± standard deviation unless
stated otherwise. Student’s t test or, where appropriate,
two-way analysis of variance followed by Bonferroni's
post-hoc test was used to compare groups. P values of
<0.05 were considered statistically significant.
Results
Phenotype of CD40-activated B cells
Upon activation via CD40 B cells upregulate the expres-
sion of MHC class II, costimulatory molecules, and ad-
hesion molecules and as a consequence they acquire
potent T-cell stimulatory activity. We therefore first
studied the effect of IL-10, TGF-β, and VEGF on the
morphology and cell surface expression of HLA-DR and
costimulatory molecules of CD40-activated B cells. The
upregulation of adhesion molecules such as ICAM-1
results in the formation of round clusters through
homotypic adhesion of activated B cells. As shown in
Figure 1 IL-10, TGF-β, and VEGF had no impact on
cluster formation of CD40-activated B cells.
For the same activation protocol used in this work
we have repeatedly shown a strong upregulation of
CD80, CD86 and HLA-DR both for B cells of healthy
donors and of cancer patients [28,29]. Thus, we used
the expression levels of vehicle treated CD40-activated
B-cells as baselines and these were compared to the
expression levels of cells exposed to the immunosuppres-
sive cytokines. In a series of experiments no statistically
significant differences between CD40-activated B cells
treated with IL-10, TGF-β, or VEGF in comparison to
controls were observed (Figure 2).
Proliferation of CD40-activated B cells
Activation via CD40 induces proliferation of B cells. We
assessed whether the proliferation was inhibited by any
of the three immunosuppressive factors. Table 1Figure 1 Morphology of CD40-activated B cells. Cluster
formation of CD40-activated B cells through homotypic adhesion is
not affected by IL-10, TGF-β, or VEGF for 4 days.
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Figure 2 Phenotype of CD40-activated B cells. CD40-activated B
cells were cultured on CD40L-expressing NIH3T3 fibroblasts in the
presence of 40 ng/ml IL-10, 10 ng/ml TGF-β, 20 ng/ml VEGF or
vehicle. After 4 days in culture the surface expression of HLA-DR and
the costimulatory molecules CD80 and CD86 by CD40-activated B
cells was assessed by flowcytometry. Shown is the mean
fluorescence intensity relative to vehicle-treated CD40-activated B
cells. The bar graph shows the means of 6 independent
experiments ± SD.
Table 1 Proliferation of CD40-activated B cells
Mean (%) SD p
Control 197 +/− 52 -
IL-10 301 +/− 106 < 0.01
TGF-β 222 +/− 95 Not significant
VEGF 197 +/− 70 Not significant
Means of the relative increase in cell number of 8 experiments.
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activated B cells cultured in the presence of either IL-10,
TGF-β, or VEGF. After four days the cells were removed
from the wells and the proliferation was determined by
counting. TGF-β and VEGF exerted no effect on the
proliferation of B cells activated through CD40. Consist-
ent with previous reports we found that IL-10 enhanced






Migration of APCs to the secondary lymphoid organs is
essential for the induction of CD4+ and CD8+ T cell
responses. For CD40-activated B cells of healthy donors
and of cancer patients the migration capacity has been
shown [28,31]. We thus studied the influence of IL-10,
TGF-β, and VEGF on the migratory ability of CD40-
activated B cells towards the important lymph node
homing cytokines SDF-1α and SLC in vitro. We used
the migration of vehicle treated CD40-activated B cells
as controls (relative migration =1). The T cell migration
of CD40-activated B cells treated with IL-10, TGF-β, or
VEGF in comparison to these controls are shown in
Figure 3. CD40-activated B cells migrated equally well
towards SDF-1α and SLC independent of whether they
were treated with vehicle, IL-10, TGF-β, or VEGF.0 1 2 3
Relative migration
Figure 3 Migratory ability of CD40-activated B cells. 5 × 105
CD40-B cells were added to the upper chamber transwell plates.
Varying amounts of the chemokines SDF-1α and SLC (R&D Systems)
were added to the lower chamber. After 2 hours the cells that had
migrated into the lower chamber were counted with a
hemacytometer. The migration index is calculated relative to vehicle-
treated controls. Shown are the means of 4 independent
experiments ± SD.T cell stimulation by CD40-activated B cells
In order to assess the impact of tumor-derived immuno-
suppressive factors on the T cell-stimulatory capacity of
CD40-activated B cells we compared the ability of
CD40-activated B cells which were treated with IL-10,
TGF-β, or VEGF to induce the proliferation of CFSE-
labeled CD4+ or CD8+ T lymphocytes from healthy
HLA-mismatched donors. Figure 4 shows the result of
the CFSE-proliferation assays comparing vehicle con-
trols with CD40-activated B cells which were exposed
to IL-10, TGF-β, or VEGF. We did not observe statis-
tically significant differences in the proliferation of
CD4+ or CD8+ T cells between the controls and
CD40-activated B cells which were cultured in the
presence of 40 ng/ml IL-10, 10 ng/ml TGF-β, or
20 ng/ml VEGF. Therefore, neither IL-10, TGF-β, nor
VEGF was able to inhibit the capacity CD40-activated
B cell to activate CD4+ or CD8+ T lymphocytes.Discussion
Due to a growing body of knowledge about immunosur-
veillance – and loss thereof – anti-tumor immunother-
apy has been refined [32]. Nevertheless, especially
results of APC-based tumor vaccination trials often
have often not met the high expectations. Lack of effi-
cacy mainly originates from well-defined tumor escape






































Figure 4 T cell-stimulatory capacity of CD40-activated B cells. 1
x 104 treated and control CD40-activated B cells were incubated
with 1 x 105 CFSE-labeled allogeneic T cells. After 5 days the
proliferation of the allogeneic CD4+ and CD8+ T cells was assessed
by flow cytometery. IL-10, TGF-β, or VEGF did not inhibit the
proliferation of allogeneic CFSE-labeled CD4+ (n = 8) and CD8+ T
cells (n = 5) in response to CD40-activated B cells. The data shown
represents the means of the relative percentage of CD25+
proliferating, i.e. CFSElow, T cells ± SD.
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derived cytokines inducing tolerogenic DC, e.g. by trigger-
ing myeloid DC B7-H1 expression [34], and by recruit-
ment of regulatory T cells [35], myeloid-derived
suppressor cells (MDSCs) and mesenchymal stroma cells
(MSCs) [36]. IL-10, TGF-β, and VEGF all have been
identified as key factors that mediate the inhibitory ac-
tion of the tumor microenvironment. Their serum
levels are frequently increased in cancer patients and
the tumor tissues of many cancer types are enriched for
these immunosuppressive factors [37–39]. The main ac-
tivity of IL-10 is related to downregulation of T cell
function, which occurs predominantly through indirect
mechanisms involving APCs [40]. IL-10 has been shown to
impair antigen-presentation by DCs through reduction of
the cell surface expression of adhesion and costimulatorymolecules as well as MHC class II. Furthermore, IL-10 pro-
motes DC apoptosis and inhibits DC migration to the sec-
ondary lymphoid organs [41,42]. DCs isolated from
transgenic mice that over-express IL-10 have a defect in
antigen presentation and decreased capacity to induce T cell
activation. Conversely, in IL-10-deficient tumor-bearing
mice the defect in DC function was reversed [43]. As a con-
sequence IL-10-conditioned DCs are tolerogenic and in-
duce T cell anergy [6,44]. Like IL-10 TGF-β prevents the
trafficking of DCs to the lymph nodes [45]. In addition,
TGF-β impairs the maturation of DCs and thereby leads to
the accumulation of immature DCs with the ability to gen-
erate regulatory T cells [8,46]. VEGF also inhibits DC mat-
uration leading to an accumulation of immature DCs with
impaired APC function within the tumor microenviron-
ment and the tumor-draining lymph nodes [9]. Conse-
quently, inhibition of TGF-β, IL-10, or VEGF signaling
improves DC function and enhances the efficacy of tumor
vaccines [47–49]. Another strategy to address these tumor
escape mechanisms in cellular tumor vaccinations is the
use of alternative APC sources. In this context human
CD40-activated B cells have gained increasing interest.
We and others have previously shown that CD40-acti-
vated B cells are equipped with a profile of chemokine
receptors that are required for the homing to the secondary
lymphoid organs [31]. Furthermore, CD40-activated B cells
are potent antigen-presenting cells and are able to prime
both CD4+ and CD8+ T cells in vitro. The capacity of
CD40-activated B cell-based cancer vaccine to induce CD4+
and CD8+ T cell responses also has been shown in vivo in
mice and a large animal model in dogs [22,25,27,50,51]. An
important advantage of CD40-activated B cells is that they
can be highly expanded at relatively low cost from small
amounts of peripheral blood even from cancer patients
[21,28]. Nevertheless, it has also has been proposed that
their APC functions have to be further evaluated in more
detail before they are used in therapeutic vaccinations [52].
It is known that IL-10, TGF-β, and VEGF play im-
portant roles in the regulation of B cells. TGF-β spe-
cifically induces the class switch to IgA while IL-10
promotes switching to IgA, IgG, and IgE [53]. TGF-β
furthermore induces apoptosis in resting B cells and
inhibits B cell proliferation [54]. VEGF leads to the
accumulation of B cells in the spleen [55]. However,
compared to DCs the influence of these immunosup-
pressive cytokines on CD40-activated B cells is poorly
characterized. We therefore studied the effects of IL-10,
TGF-β, and VEGF on crucial steps in the generation of
a T cell-mediated immune response in vitro. Neither
TGF-β nor VEGF had a significant effect on B cell
proliferation. Exposure to IL-10 on the other hand
increased the expansion of B lymphocytes. The migratory
ability of B cells remained unchanged after exposure to all
the three immunosuppressive factors. Even though it was
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ine and human B cells [56] the activation by CD40 seems
to protect B cells from the inhibitory effect of IL-10. For
TGF-β our findings supports assumptions from previous
reports that some of the immunosuppressive effects on B
cells can be blocked by CD40 signaling [57,58]. Thus, with
the notable exception of the enhancing effect of IL-10 on
B cell proliferation important APC functions of CD40-
activated B cells are not affected by IL-10, TGF-β, or
VEGF.
Conclusion
In summary, our results show that at least in vitro the
APC function of CD40-activated B cells is highly resist-
ant to inhibition by the immunosuppressive factors IL-
10, TGF-β, and VEGF, which have been shown to play an
important role in the immunosuppressive microenviron-
ment of many tumors and to interfere with the differen-
tiation and APC function of DCs. Thus, ex vivo
generated CD40-activated B cells are well suited as APCs
for cellular vaccines. They represent a promising alterna-
tive or additional APC for cellular immunotherapy, espe-
cially in settings where the above cytokines are present
in the tumor microenvironment.
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